Morgan Stanley’s Checkpoint Therapeutics CKPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-48,931
| Closed | -$198K | – | 8127 |
|
|
2025
Q1 | $198K | Sell |
48,931
-238,060
| -83% | -$794K | ﹤0.01% | 5730 |
|
|
2024
Q4 | $918K | Buy |
286,991
+183,332
| +177% | +$622K | ﹤0.01% | 5132 |
|
|
2024
Q3 | $232K | Buy |
103,659
+93,000
| +873% | +$215K | ﹤0.01% | 5699 |
|
|
2024
Q2 | $22.9K | Hold |
10,659
| – | – | ﹤0.01% | 6414 |
|
|
2024
Q1 | $21.9K | Sell |
10,659
-5,539
| -34% | -$11K | ﹤0.01% | 6462 |
|
|
2023
Q4 | $37.1K | Buy |
16,198
+9,275
| +134% | +$20.2K | ﹤0.01% | 6467 |
|
|
2023
Q3 | $11.8K | Buy |
6,923
+871
| +14% | +$1.98K | ﹤0.01% | 6669 |
|
|
2023
Q2 | $14.9K | Buy |
6,052
+37
| +0.6% | +$101 | ﹤0.01% | 6660 |
|
|
2023
Q1 | $13.5K | Buy |
6,015
+4,852
| +417% | +$24.4K | ﹤0.01% | 6773 |
|
|
2022
Q4 | $5.94K | Sell |
1,163
-1,499
| -56% | -$10.8K | ﹤0.01% | 7106 |
|
|
2022
Q3 | $28K | Sell |
2,662
-360
| -12% | -$4.29K | ﹤0.01% | 6648 |
|
|
2022
Q2 | $32K | Sell |
3,022
-821
| -21% | -$10.8K | ﹤0.01% | 6810 |
|
|
2022
Q1 | $68K | Sell |
3,843
-2,259
| -37% | -$48.5K | ﹤0.01% | 6542 |
|
|
2021
Q4 | $190K | Sell |
6,102
-5,702
| -48% | -$189K | ﹤0.01% | 6102 |
|
|
2021
Q3 | $390K | Sell |
11,804
-6,907
| -37% | -$204K | ﹤0.01% | 5644 |
|
|
2021
Q2 | $552K | Sell |
18,711
-20,672
| -52% | -$573K | ﹤0.01% | 5467 |
|
|
2021
Q1 | $1.24M | Sell |
39,383
-11,609
| -23% | -$389K | ﹤0.01% | 4596 |
|
|
2020
Q4 | $1.35M | Buy |
50,992
+48,896
| +2,333% | +$1.24M | ﹤0.01% | 4465 |
|
|
2020
Q3 | $56K | Buy |
2,096
+333
| +19% | +$8K | ﹤0.01% | 5683 |
|
|
2020
Q2 | $35K | Buy |
1,763
+991
| +128% | +$18.1K | ﹤0.01% | 5804 |
|
|
2020
Q1 | $12K | Sell |
772
-2,582
| -77% | -$45.7K | ﹤0.01% | 5971 |
|
|
2019
Q4 | $58K | Buy |
3,354
+2,609
| +350% | +$43.7K | ﹤0.01% | 5816 |
|
|
2019
Q3 | $18K | Buy |
745
+500
| +204% | +$13.7K | ﹤0.01% | 6041 |
|
|
2019
Q2 | $7K | Buy |
245
+145
| +145% | +$5.69K | ﹤0.01% | 6222 |
|
|
2019
Q1 | $3K | Sell |
100
-280
| -74% | -$8.94K | ﹤0.01% | 6393 |
|
|
2018
Q4 | $7K | Buy |
380
+192
| +102% | +$4.57K | ﹤0.01% | 6236 |
|
|
2018
Q3 | $7K | Sell |
188
-14
| -7% | -$489 | ﹤0.01% | 6368 |
|
|
2018
Q2 | $6K | Sell |
202
-612
| -75% | -$21.2K | ﹤0.01% | 6397 |
|
|
2018
Q1 | $36K | Buy |
+814
| New | +$35.3K | ﹤0.01% | 5974 |
|
Morgan Stanley's CKPT Position: Q2 2025 in Review
Morgan Stanley sold out of Checkpoint Therapeutics (CKPT) in Q2 2025, closing a stake of 48,931 shares — an estimated $198K sold.
Morgan Stanley first reported a position in CKPT in Q1 2018 and held it in 29 quarters. The position peaked at $1.35M in Q4 2020. 0 funds tracked by Wall St. Rank hold CKPT as of Q2 2025.
- Morgan Stanley reported no remaining Checkpoint Therapeutics position as of Q2 2025 after selling out during the quarter.
- Morgan Stanley sold 48,931 Checkpoint Therapeutics shares in Q2 2025, an estimated $198K.
- Morgan Stanley first reported a position in Checkpoint Therapeutics in Q1 2018 and held it in 29 quarters.
- Morgan Stanley's Checkpoint Therapeutics position peaked at $1.35M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2025.
Based on Morgan Stanley's 13F filing for Q2 2025, filed 15 Aug 2025.